Comments
Sanofi draws fire over cost of MS drug Lemtrada
01.11.2012. | PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators....
